SCHEMBL6093728

SCHEMBL6093728

Cc1ccccc1C(=O)c1ccc(Nc2ccccc2OCCCO)cc1Cl

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.68
MAPK13 O15264 13/20 0.68
MAPK12 P53778 13/20 0.68
MAPK11 Q15759 13/20 0.68
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.40
AVPR2 P30518 1/20 0.40
OXTR P30559 1/20 0.40
AVPR1A P37288 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
POLB P06746 1/20 0.40
CYP2C19 P33261 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6097286 0.89 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11NPC1
SCHEMBL6098369 0.85 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1906353 0.85 MAPK14 (0.77) MAPK14MAPK13MAPK12MAPK11MEN1
SCHEMBL6098502 0.83 MAPK13 (0.57) MAPK14MAPK13MAPK12MAPK11POLB
SCHEMBL6097137 0.83 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11SIRT2
SCHEMBL6820653 0.83 MAPK14 (0.71) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL1907624 0.83 MAPK14 (0.74) MAPK14MAPK13MAPK12MAPK11MAPT
SCHEMBL1904637 0.82 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL6093751 0.81 MAPK14 (0.54) MAPK14MAPK13MAPK12MAPK11MEN1
SCHEMBL6816785 0.81 MAPK14 (0.68) MAPK14MAPK13MAPK12MAPK11AVPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US claimed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP claimed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US claimed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO claimed
US-7034015-B2 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2006-04-25 US disclosed
EP-1423356-A2 NOVEL AMINOBENZOEPHENONES Leo Pharma A/S (DK) 2004-06-02 EP disclosed
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors LEO PHARMA A/S (DK) 2003-06-26 US disclosed
WO-2003018535-A2 NOVEL AMINOBENZOEPHENONES LEO PHARMA A/S (DK) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119902-A1 Interleukin 1 beta and tumour necrosis factor alpha inhibitors IL1B, IL1A, TNF MAPK14 1972/4885MAPK13 2918/4885MAPK12 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.